Chemotherapy‐induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors

Citations Over TimeTop 13% of 2022 papers

Abstract

Among BrCa survivors, CIPN onset is associated with a subsequent increased 12-month risk of depression and anxiety. Depression and anxiety screening should be considered in BrCa+/CIPN+ survivors, particularly given their known impact on fall risk. The observed association between CIPN and an increased risk of depression and anxiety should be further studied in prospective studies.

Related Papers

• → Rates of Comorbid Anxiety and Depression in Patients With Age-Related Macular Degeneration(2019)5 cited
• → Improvement in quality of life by using duloxetine for chemotherapy-induced peripheral neuropathy (CIPN): a case report(2016)12 cited
• [Chemotherapy-induced peripheral neuropathy; impact on quality of life].(2014)
• Influence of Health Education on Type 2 Diabetic Inpatients' Anxiety and Depression(2013)
• → Chemotherapy-Induced Peripheral Neuropathy and Treatment(2023)